Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

M.G. Bousser; P. Amarenco; A. Chamorro; M. Fisher; I. Ford; K. Fox; M. Hennerici; H.P. Mattle; L.J. Kappelle; P.M. Rothwell

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

Translated title of the contribution: Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

M.G. Bousser, P. Amarenco, A. Chamorro, M. Fisher, I. Ford, K. Fox, M. Hennerici, H.P. Mattle, L.J. Kappelle, P.M. Rothwell

Neurology & Neurosurgery

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study
Original language	Undefined/Unknown
Pages (from-to)	509-518
Number of pages	10
Journal	Cerebrovascular Diseases
Volume	27
Issue number	5
Publication status	Published - 2009

Cite this

Bousser, M. G., Amarenco, P., Chamorro, A., Fisher, M., Ford, I., Fox, K., Hennerici, M., Mattle, H. P., Kappelle, L. J., & Rothwell, P. M. (2009). Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases, 27(5), 509-518.

Bousser, M.G. ; Amarenco, P. ; Chamorro, A. et al. / Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. In: Cerebrovascular Diseases. 2009 ; Vol. 27, No. 5. pp. 509-518.

@article{b53a7d2958cf4aa5bdb3e1c8cb498b41,

title = "Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study",

author = "M.G. Bousser and P. Amarenco and A. Chamorro and M. Fisher and I. Ford and K. Fox and M. Hennerici and H.P. Mattle and L.J. Kappelle and P.M. Rothwell",

year = "2009",

language = "Undefined/Unknown",

volume = "27",

pages = "509--518",

journal = "Cerebrovascular Diseases",

issn = "1015-9770",

publisher = "S. Karger AG",

number = "5",

}

Bousser, MG, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, K, Hennerici, M, Mattle, HP, Kappelle, LJ & Rothwell, PM 2009, 'Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study', Cerebrovascular Diseases, vol. 27, no. 5, pp. 509-518.

Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. / Bousser, M.G.; Amarenco, P.; Chamorro, A. et al.
In: Cerebrovascular Diseases, Vol. 27, No. 5, 2009, p. 509-518.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study

AU - Bousser, M.G.

AU - Amarenco, P.

AU - Chamorro, A.

AU - Fisher, M.

AU - Ford, I.

AU - Fox, K.

AU - Hennerici, M.

AU - Mattle, H.P.

AU - Kappelle, L.J.

AU - Rothwell, P.M.

PY - 2009

Y1 - 2009

M3 - Article

SN - 1015-9770

VL - 27

SP - 509

EP - 518

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

IS - 5

ER -

Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox K et al. Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovascular Diseases. 2009;27(5):509-518.